



Massachusetts Department of Public Health
Bureau of Infectious Disease and Laboratory Sciences

Surveillance, Reporting and Control of Vaccine-Preventable Diseases A Partnership

Adult Immunization Conference

“Building Networks to Vaccinate the Village”

April 25, 2017

Joyce Cohen, MPH

joyce.cohen@state.ma.us

Marija PopStefanija, MPH

marija.popstefanija@state.ma.us



Presenter Disclosure Information

We, **Joyce Cohen and Marija PopStefanija**, have been asked to disclose any significant relationships with commercial entities that are either providing financial support for this program or whose products or services are mentioned during our presentations.

We have no relationships to disclose.

We will discuss the use of vaccines in a manner not approved by the U.S. Food and Drug Administration.

But in accordance with ACIP recommendations.

Today's Topics

- **Vaccine-preventable disease (VPD) epidemiology in Massachusetts**
 - Overall trends
 - Influenza
 - Congenital rubella syndrome (CRS)
 - Invasive meningococcal disease
 - Mumps
- **One village's experience – Mumps 2016**



COLLABORATIONS IN DISEASE SURVEILLANCE AND CONTROL



Healthcare Provider



LBOH 1



MDPH

LBOH 2



Sports Team



School



Massachusetts Department of Public Health

Bureau of Infectious Disease and Laboratory Sciences - Division of Epidemiology and Immunization

Vaccine-Preventable Diseases in Massachusetts*, 2007-2016

Disease	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
Measles	1	2	2	3	24	0	1	8	0	1
Mumps	6	7	15	9	4	6	71	5	6	253
Rubella	1	1	1	0	1	1	0	0	0	0
CRS	0	0	0	0	0	0	0	0	0	0
Meningococcal Disease	21	22	14	8	14	6	11	11	12	11
Pertussis	1198	762	362	294	273	651	348	298	252	193
Hib < 5	3	2	1	1	0	2	1	1	0	1
Tetanus	0	0	0	0	0	0	0	0	0	0
Diphtheria	0	0	0	0	0	0	0	0	0	0
Polio	0	0	0	0	0	0	0	0	0	0
Pneumococcal Disease < 5	89	83	81	72	40	51	24	27	20	31
Varicella	2094	1585	1415	769	606	626	476	469	356	289


Data are current as of 4/7/2017 and are subject to change.

*Both confirmed and probable cases are reported for measles, mumps, rubella, and varicella to better reflect the true burden of disease. All other diseases include confirmed cases only.

2016-2017 Influenza Season

- Moderate season – Influenza A (H3N2) predominated this season.
- Circulating strains were a good match with the vaccine. Overall vaccine effectiveness (VE) against influenza A and influenza B virus infection associated with medically attended acute respiratory illness (ARI) was 48%.
- Influenza activity in Massachusetts peaked in February.

Influenza Hospitalizations in the United States




The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-associated hospitalizations in children (persons younger than 18 years) and adults. The current network covers over 70 counties in the 10 Emerging Infections Program (EIP) states (CA, CO, CT, GA, MD, MN, NM, NY, OR, and TN) and three additional states (MI, OH, and UT). The network represents approximately 9% of US population (~27 million people). Cases are identified by reviewing hospital, laboratory, and admission databases and infection control logs for patients hospitalized during the influenza season with a documented positive influenza test (i.e., viral culture, direct/indirect fluorescent antibody assay (DFA/IFA), rapid influenza diagnostic test (RIDT), or molecular assays including reverse transcription-polymerase chain reaction (RT-PCR)). Data gathered are used to estimate age-specific hospitalization rates on a weekly basis, and describe characteristics of persons hospitalized with associated influenza illness. Laboratory confirmation is dependent on clinician-ordered influenza testing. Therefore, the unadjusted rates provided are likely to be underestimated as influenza-associated hospitalizations can be missed if influenza is not suspected and tested for. FluSurv-NET hospitalization data are preliminary and subject to change as more data become available. All incidence rates are unadjusted. Please use the following citation when referencing these data: "FluView: Influenza Hospitalization Surveillance Network, Centers for Disease Control and Prevention. WEBSITE. Accessed on DATE".

Source: CDC

Massachusetts Influenza-like Illness (ILI) as of 4/8/2017

Figure 1: Percentage of ILI visits reported by sentinel provider sites



*Influenza-like illness (ILI, defined by fever >100F and cough and/or sore throat), as reported by Massachusetts sentinel surveillance sites

Congenital Rubella Syndrome (CRS)

- Maternal rubella infection, especially during the first trimester can cause multiple serious birth defects in the fetus. Baby can remain infectious for one year or longer.
- Rare in the US.
- **2017: First Massachusetts case in over 20 years.**
 - Born in February in an outlying hospital.
 - Mother from Africa: one US prenatal visit prior to delivery.
 - Came to MA for delivery.
 - Was tested for rubella immunity and had a very high positive IgG. Mostly likely had rubella in first trimester.

CRS In the US and Worldwide

- More than **100,000** children are born every year with CRS, mainly in Africa, South-East Asia, and the Western Pacific.
- There were 41 cases of CRS reported in the US from 1998 – 2016 (18 year period). 88% of mothers were born outside the US.


A woman **infected with rubella** during the first 3 months of pregnancy has up to a

90% chance



of giving birth to a baby with **congenital rubella syndrome**

Or her baby may not survive.



300 infants a day are born with **congenital rubella syndrome**

GET VACCINATED »

Recommendations

- Immunity to rubella should be documented in **all** pregnant women.
 - Particularly in recent U.S. arrivals and foreign-born
- If not immune, or in doubt, vaccinate.
 - Before pregnancy
 - Or before discharge after delivery
 - Or at the first post-partum visit
- High index of suspicion with recent arrivals to US who were born outside of US.
 - Ask about rash illness and exposure to rash illness during pregnancy
- Consider CRS in infants with symptoms consistent with CRS, especially in foreign-born or recently-arrived mothers, and place on contact precautions.
- **Infection Control is Critical: Infants can shed the virus for prolonged periods (up to 1 year of age or longer)**

Invasive Meningococcal Disease

- Five cases in two months starting in late January 2016 among people experiencing homelessness in greater Boston
- Very cold winter
- A sixth case was retrospectively linked to the outbreak
- 4 males/2 females
- Two deaths
- Three serogroup C; three serogroup Y (matching molecular profiles) – serogroups are included in the quadrivalent meningococcal vaccine
- Very unusual outbreak



BOSTON PUBLIC HEALTH COMMISSION
Communicable Disease Control Division
1010 Massachusetts Avenue · Boston, MA 02118
Phone: (617) 534-5611 · Fax: (617) 534-5905

UPDATE: Meningococcal Disease in the Boston Adult Homeless Community

Summary: The Boston Public Health Commission (BPHC) has received reports of five confirmed cases of meningococcal disease in the Boston adult homeless community since the end of January. Four cases presented with meningococcemia; one presented with meningitis. Two cases developed fulminant disease and died. Close contacts of each case have been chemoprophylaxed. Serogrouping has been completed on four isolates:

Invasive Meningococcal Disease

- Antibiotic post-exposure prophylaxis to close contacts (**280 individuals**)
- Large vaccination campaigns – approx. **4800 doses of meningococcal vaccine were administered, the majority by the Boston Health Care for the Homeless Program**
- CDC-led case-control interviews to determine risk factors:
 - History of any immunosuppressive condition was significantly associated with IMD
 - While not statistically significant, a higher proportion of cases than controls were black, newly homeless, had higher education level, slept in rooms with ≥ 50 persons, shared beverages and food, and engaged in high risk activities such as having >1 kissing or sexual partner.

(Source: Otshudiema, John O., M.D., M.P.H. , CDC)





By Felice J. Freyer | GLOBE STAFF MARCH 16, 2016

Disease-trackers from the Centers for Disease Control and Prevention are in Boston to study the spread of a deadly bacterial infection among





UMASS Amherst Vaccination Clinic Exercise



Emergency Dispensing Site Exercise

Mumps




A systemic disease characterized by:

- Non-specific prodrome consisting of myalgia, loss of appetite, malaise, headache, low-grade fever
- Swelling of one or more salivary glands, usually the parotid glands, often tender or painful, with orchitis commonly reported in males after puberty
- **1/3 of infections may be asymptomatic or manifest as respiratory illness**
- Rare complications include arthritis, encephalitis, thyroiditis, mastitis, ataxia, oophoritis, hearing loss, and others
- **Two doses 88% effective (at best) in preventing mumps**

Confirmed and probable mumps cases in MA and in the US

Year	Cases in U.S.	Cases in MA
2006	6,584	10
2007	800	6
2008	454	7
2009	1,991	15
2010	2,612	9
2011	370	4
2012	229	6
2013	584	71
2014	1,223	5
2015	1,057*	6
2016	5,311**	253***



Source: CDC

*Cases as of January 2, 2016. Case count is preliminary and subject to change.


**Cases as of April 4, 2017. Case count is preliminary and subject to change.

Source: [Morbidity and Mortality Weekly Report \(MMWR\), Notifiable Diseases and Mortality Tables](#)

*** Cases as of December 31, 2016. Preliminary and subject to change.

Event Date of All Investigated Mumps Events by Week

January 1 2016 – December 31 2016




Data are preliminary and subject to change. (MDPH 2016)

Onset of Parotitis among Confirmed and Probable Mumps Cases by Week

Outbreak Related vs Not Outbreak Related

January 1 – December 31, 2016



Mumps in MA 2016

- Largest mumps outbreak in MA in 30+ years
 - **789** total investigations from January – December 2016
- Largely contained within university settings, with little spread into surrounding communities
- Transmission interrupted due to:
 - Enforcement of existing school requirements for immunization
 - Implementation of control measures, including social distancing
 - End of school year and school vacations

Challenges

- Many causes of parotitis
- Mumps testing shortcomings
- Asymptomatic people may transmit mumps
- Vaccination not 100% effective
- Educating providers and LBOHs
- Isolation for five days, especially with negative test results
- Social distancing/college students

Updated Mumps Chapter

- Mass.gov/dph/epi – click on “Reportable Communicable Diseases”

MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH Guide to Surveillance, Reporting and Control

Mumps

Section 1

ABOUT THE DISEASE

A. Etiologic Agent

Mumps is caused by the mumps virus (genus *Paramyxovirus*, family *Para*

Note: Swelling of the salivary glands (parotitis) can also be caused by infection with influenza A, Coxsackie A, echovirus, *Staphylococcus aureus*, lymphocytic choriomeningitis virus, and noninfectious causes such as drugs (e.g., phenylbutazone, thiouracil, iodides), tumors, starch ingestion, metabolic disorders (diabetes, cirrhosis, and malnutrition), immunologic diseases, and obstruction of the salivary duct. However, other infectious causes of parotitis do not cause epidemic parotitis.

B. Clinical Description

Mumps is a systemic disease characterized by swelling of one or more salivary glands. Parotitis tends to occur early and may first be noted as an earache on the angle of the jaw. Symptoms tend to decrease after one week and usually resolve within 10 days. Symptoms are non-specific and may include myalgia, anorexia, malaise, and headache. Approximately one-third of infections do not cause clinically apparent symptoms (subclinical) or may manifest primarily as respiratory tract infection. Inflammation of the salivary gland (parotitis) is the most common complication in postpubertal males.

In the prevaccine era, mumps accounted for approximately 10% of cases of meningitis. In the post-vaccine era, among all persons infected with mumps, encephalitis, pancreatitis, and deafness have all been less than 1%. Other permanent sequelae such as paralysis, seizures, cranial nerve palsies, and deafness. Other rare complications include arthritis, thyroiditis, mastitis, glomerulonephritis, endocardial fibroelastosis, thrombocytopenia, cerebellar ataxia, transverse myelitis, and permanent hearing impairment. Death is uncommon.

September 2016 | Page 11 of 12

Attachment One – Mumps Testing

Report suspect cases immediately

Mumps is immediately reportable in Massachusetts, whether suspected or confirmed. Call your local board of health and MDPH at 617/983-6800. Providers in Boston should contact the Boston Public Health Commission at 617/534-5611.

When to test for mumps:

A clinical diagnosis of mumps must be confirmed by laboratory testing. Consider lab testing for patients with symptoms consistent with mumps:

- Low-grade fever
- Swelling of one or more salivary glands, usually the parotid gland, and/or orchitis and
- A prodrome consisting of myalgias, loss of appetite, malaise, and/or headache

Patients with fever, swelling and contact to a known mumps case or outbreak should be given high priority for testing. Asymptomatic patients should not be tested for mumps.

Note: Swelling of the salivary glands (parotitis) can also be caused by infection due to parainfluenza virus types 1 and 3, influenza A, Coxsackie A, echovirus, *Staphylococcus aureus*, lymphocytic choriomeningitis virus, HIV, and noninfectious causes such as drugs (e.g., phenylbutazone, thiouracil, iodides), tumors, starch ingestion, metabolic disorders (diabetes, cirrhosis, and malnutrition), immunologic diseases, and obstruction of the salivary duct. Consider testing for these other causes of parotitis.

Isolate the patient: Mask and isolate the suspect patient as much as possible and consolidate care using standard and droplet precautions. Clinicians should also be masked. Suspected cases of mumps should be asked to refrain from all public activities for five days following onset of swelling.

What specimens should be collected?

In general, when mumps is suspected, MDPH recommends the collection of serum for mumps immunoglobulin M (IgM) testing and a swab of the buccal region (“buccal swab” (BS)) for mumps PCR testing. The buccal swab is the preferred specimen for mumps PCR testing, obtained as soon as possible after onset of parotitis. The specimen should be sent to the Massachusetts State